Improving and protecting the public health
by strengthening education and training
of public health professionals
for both practice and research
Remember me

The Association of Schools of Public Health in the European Region (ASPHER)

ASPHER is the key independent European organisation dedicated to strengthening the role of public health by improving education and training of public health professionals for both practice and research.
Home » ASPHER Statement on the COVID-19 Testing


5 Apr 2024
Friday, April 12
Event summary We are faced with an emerging set of public health challenges due to war and conflict, as a result of political instability and climate catastrophe. Injury and death, and the physical and psychological impact of violence...
29 Mar 2024
Tuesday-Friday 11-14 June, Brussels
Who is ASSETS for?
Ambitious early career public health professionals (whether from academia/junior faculty and advanced students, or graduates in city/regional administration, national civil service, private...
25 Mar 2024
Brussels, 25 March 2024
For Immediate Release:
Enhancing European Public Health Preparedness, Pre-Hospital, and Disaster Medicine International organisations, experts and stakeholders come together for urgent interdisciplinary...

ASPHER Statement on the COVID-19 Testing

Recommended citation: Pinto da Costa J, Barros H, Middleton J, et al. ASPHER Statement on the COVID-19 testing. ASPHER (2020).

Download the PDF Version of the Statement

For an in depth report, please see: Pinto da Costa J, Barros H, Middleton J, et al. COVID-19 testing: A reflection on test accuracy in the real world. ASPHER (2020).

Download a PDF of the COVID-19 testing decision tree.

See the bibliography of recent publications on COVID-19 testing below.

Testing is essential to understand the dynamics of COVID-19 in the population, to plan preventive measures, and to provide the basis for appropriate therapeutic measures. After the identification of the SARS-CoV-2 virus and the clinical definition of COVID-19, there was a rapid development of diagnostic and screening tools. Their accuracy needs to be assessed carefully as the interpretation of results could have profound impacts on individual and public health decision-making. We reviewed the information available on the performance of existing tests to identify the virus (molecular tests) or its immunological expression (serological tests). The major findings and concerns are highlighted below:

Molecular tests for clinical cases and contact tracing

  1. Molecular tests - reverse transcription-polymerase chain reaction (RT-PCR) - are essential to confirm a COVID-19 case – to trace contacts, to isolate, and subsequently, to confirm viral clearance, as decisions based on clinical resolution do not seem to match the viral clearance from testing;
  2. A meta-analysis cited in this report estimated the pooled sensitivity to RT-PCR as 89% (95%CI: 81-94%);
  3. This should lead us to be cautious about the proportion of reported false negatives. The performance of RT-PCR tests, whether for diagnosis or screening, is a very important concern. False positive results will lead only to a degree of inconvenience for the individuals who have positive results. However, a large number of individuals with false negative results allowed back into general society, or into health and social care, could have a considerable impact and the opportunity for the spread of the virus into susceptible individuals.
  4. In the peak period of the pandemic passing through communities, mass testing and contact tracing may not be practicable, and the advice to individuals will be the same regardless of a test result, namely self-isolation.
  5. However, there will be a place for reintroduction of testing and contact tracing as numbers reduce, such that countries are looking to reduce lockdown and isolation procedures, and sufficient staffing resources and test kits permit.

Serological tests for case confirmation and advice for contacts and key workers

  1. Serological tests are a potential tool that can be used in large scale surveillance efforts to estimate the prevalence of the population ever exposed to the virus, which is expected to be much higher than those diagnosed at any one moment.
  2. The presence of antibodies for SARS-CoV-2 does not exclude that the individual may remain infectious due to recent infection, thus, clinical and epidemiological history should also be considered in relation to serological testing.
  3. The reliability of serological tests needs to be checked and further development of serological tests is needed. For example, if we are to pursue the idea of an “immunity passport” – this will rely critically on clear evidence of long-lasting immunity.

Serological testing for whole populations

  1. Interpretation of test results must be careful and cautious, whether for individuals or whole populations;
  2. The positive predictive value is the proportion of all positive tests which are true positive cases. This figure is more reliable when there is a high prevalence of virus circulating in the community. However, as we test more people, we will find large numbers of false positive results, even if the test is thought to have a high specificity. Our estimates of how much virus there is in communities will be very difficult. We do not know if the high figures being quoted in some studies represent a high level of asymptomatic infections or a high level of false positive tests.
    The assessment of false positives becomes especially important in this situation - as an overestimate of the degree of a previous infection could allow relaxation of controls too soon.
  3. An assessment of the extent of spread would be very important in assessing the level of immunity in the population, and the likely impact of relaxing physical distancing and other lockdown measures.
  4. An international consensus on what the population parameters are when the relaxation from lockdown might start would be desirable.
  5. Testing alone is not a panacea. Testing must always be considered as part of the range of public health, non-pharmaceutical measures available to respond to the current pandemic;
  6. A major effort is needed to transparently communicate to the public the issues of testing effectiveness. The public needs and deserves to understand the issues of testing effectiveness and efficiency including what is meant by sensitivity, specificity, and predictive values.

ASPHER calls on the Faculties and Research Centers throughout Europe to contribute to fill the knowledge gaps that have been identified in relating to COVID-19 testing. Much work is already underway and with new information becoming rapidly available. ASPHER will work to keep a bibliography of recent resources below.


ASPHER Statement on Testing in the press:

Politico: The 'hard slog' of waiting for a coronavirus vaccine. Experts say mass testing, contact tracing, COVID treatments and basic public health are just as important.

Bibliography of recent resources 

(Disclaimer: There is currently a great deal of work being undertaken to inform on various aspects of the COVID-19 epidemic. In an effort to keep up to date on the most recent developments, we will be listing recent publications that have became available since the publication of the ASPHER Testing Report. This is not an official endorsement of any one study or publication.)

Huggett J, Harris K, McHugh T, et al. (2020) Diagnostic test for covid-19 – improving accuracy and global harmonisation. The BMJ Opinion.